You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
For in vitro diagnostic use. Others Elecsys IGRA SARS-CoV-2 IVD Elecsys® IGRA SARS-CoV-2 PID00000325 09542485190 IGRA SARS-CoV-2 Elecsys E2G 300 Elecsys IGRA SARS-CoV-2 07613336203279 Reagents, kits 300 tests cobas e 402/801 undefined 09542477190 IGRA SARS-CoV-2 Elecsys cobas e 200 Elecsys IGRA SARS-CoV-2 07613336203262 Reagents, kits 200 tests cobas e 411/601/602 true 09542485500 Elecsys IGRA SARS-CoV-2 en 5 FF000000065AE80E FF000000057FE50E 09542485190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe Elecsys IGRA SARS‑CoV‑2 test combines in vitro T cell stimulation using SARS‑CoV‑2 antigens in the cobas IGRA SARS‑CoV‑2 Tubes and an automated electrochemiluminescence immunoassay (“ECLIA”) for interferon gamma to qualitatively detect T cell-mediated immune response to SARS‑CoV‑2 in human whole blood. The Elecsys IGRA SARS‑CoV‑2 test is intended as an aid in identifying individuals with an adaptive T cell response to SARS‑CoV‑2, indicative of past exposure to the virus or COVID‑19 vaccination.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09542477500 Elecsys IGRA SARS-CoV-2 en 5 FF000000065B6A0E FF000000058B420E 09542477190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useThe Elecsys IGRA SARS‑CoV‑2 test combines in vitro T cell stimulation using SARS‑CoV‑2 antigens in the cobas IGRA SARS‑CoV‑2 Tubes and an automated electrochemiluminescence immunoassay (“ECLIA”) for interferon gamma to qualitatively detect T cell-mediated immune response to SARS‑CoV‑2 in human whole blood. The Elecsys IGRA SARS‑CoV‑2 test is intended as an aid in identifying individuals with an adaptive T cell response to SARS‑CoV‑2, indicative of past exposure to the virus or COVID‑19 vaccination.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en